NCT07220642

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully during the study. For each participant, the study will last for about 1 year and 6 months.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	Cagrilintide	Cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.
DRUG	Placebo	Placebo matched to cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.

Timeline

• Start date: 2025-11-05
• Primary completion: 2027-05-11
• Completion: 2027-06-29
• First posted: 2025-10-24
• Last updated: 2026-04-08

Locations

40 sites across 10 countries: United States, Argentina, Australia, Canada, France, Germany, Italy, Norway, Poland, United Kingdom

Regulatory

• FDA-regulated drug study